Prolonged cell cycle arrest by the CDK4/6 antagonist narazaciclib restores ibrutinib response in preclinical models of BTKi‐resistant mantle cell lymphoma von Profitós‐Pelejà, N., Ribeiro, M. L., Parra, J., Fernández‐Serrano, M., Marín‐Escudero, P., Makovski‐Silverstein, A., Cosenza, S., Esteller, M., Roué, G.

Volltext

Loss of RHOA impairs lenalidomide antitumor activity in mantle cell lymphoma von Carvalho Santos, J., Profitós Pelejà, N., Caillot, M., Sánchez Vinces, S., Sola, B., Lima Ribeiro, M., Roué, G.

Volltext

368 (PB356): Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell... von de Pablo, G. Gorjón, Montagut, A.M., Armengol, M., Combes-Soia, L., Burlet-Schiltz, O., Profitós-Pelejà, N., Fernández-Serrano, M., Farrès, J., Lutz, P.G., Estrada-Tejedor, R., Borrell, J.I., Roué, G.

Volltext

ANTITUMORAL ACTIVITY OF THE NOVEL BTK INHIBITOR TG‐1701 IS ASSOCIATED WITH DISRUPTION OF IKAROS SIGNALING AND IMPROVEMENT OF ANTI‐CD20 THERAPY IN B‐CELL NON‐HODGKIN LYMPHOMA... von Ribeiro, M. L, Reyes‐Garau, D, Vinyoles, M, Profitos‐Peleja, N, Santos, J. C, Armengol, M, Fernandez‐Serrano, M, Bech‐Serra, J. J, Blecua, P, Musulen, E, De la Torre, C, Miskin, H, Esteller, M, Bosch, F, Menendez, P, Normant, E, Roue, G

Volltext